Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimen
Authors:
- Catia MarzoliniCatia Marzolini
- Matthias CavassiniMCMatthias Cavassini
- Dominique L. BraunDBDominique L. Braun
- Anna HachfeldAHAnna Hachfeld
- Enos BernasconiEBEnos Bernasconi
- Alexandra CalmyACAlexandra Calmy
- Patrick SchmidPSPatrick Schmid
- Manuel BattegayMBManuel Battegay
- Luigia ElziLELuigia Elzi
- the Swiss HIV Cohort StudyTSthe Swiss HIV Cohort Study
Open Access
- 12 May 2023
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (9) , 2739-2746
Abstract
Aims: We previously observed that some individuals on HIV boosted protease inhibitor‐containing regimen do not achieve their lipid targets despite elevated statin concentrations. This study evaluated whether the common single polymorphism c.521T>C in SLCO1B1, associated with reduced statin uptake in the liver, could explain this observation.Methods: People living with HIV in the Swiss HIV Cohort Study were eligible if they were on a boosted protease inhibitor concomitantly with a statin for at least 6 months and if their SLCO1B1 genotype was available. Furthermore, their lipids had to be documented before and after the introduction of the statin. The statin efficacy was defined as % change in total cholesterol, low‐density lipoprotein–cholesterol, high‐density lipoprotein–cholesterol and triglycerides levels after statin initiation compared to pretreatment levels. Lipid response was adjusted for differences in potency and dose between statins.Results: In total, 88 people living with HIV were included, of whom 58, 28 and 2 carried the SLCO1B1 TT, TC and CC genotypes, respectively. The change in lipid levels after statin initiation tended to be lower in carriers of the polymorphism although the difference was not statistically significant (TT vs. TC/CC: total cholesterol: −11.7 vs. −4.8%; low‐density lipoprotein– cholesterol: −20.6 vs. −7.4%; high‐density lipoprotein–cholesterol: 1.6 vs. 0%; triglycerides: −11.5 vs. −7.9%). In the multiple linear regression, change in total cholesterol was inversely correlated with the total cholesterol level prestatin treatment (coefficient −6.60, 95% confidence interval: −9.63 to −3.56, P < .001).Conclusion: The lipid‐lowering effect of statins tended to be attenuated by SLCO1B1 polymorphism and progressively declined as total cholesterol under the boosted protease inhibitor treatment decreased.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (201369)
This publication has 23 references indexed in Scilit:
- Influence ofSLCO1B1Polymorphisms on the Drug‐Drug Interaction Between Darunavir/Ritonavir and PravastatinThe Journal of Clinical Pharmacology, 2012
- Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderlyAtherosclerosis, 2012
- ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavirPharmacogenetics and Genomics, 2010
- HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsPharmacogenetics and Genomics, 2010
- Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1Xenobiotica, 2010
- Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering TherapyJACC, 2008
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Pharmacogenetics, 2004
- Polymorphisms in OATP-CJournal of Biological Chemistry, 2001